NCT02013050View on ClinicalTrials.gov

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

September 30, 2016

Conditions

Oral Mucositis

Interventions

DRUG

SGX942

DRUG

Placebo

Trial Locations (1)

40536

Markey Cancer Center-University of Kentucky, Lexington

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Soligenix

INDUSTRY